Telerobotic surgery is transitioning from experimental demonstrations to broader clinical adoption, and SS Innovations International (NASDAQ: SSII) is positioning itself as a key player in this evolving field. A recent MedTech Dive article highlighted the company's progress, noting that its SSi Mantra system has been used in 195 robotic telesurgeries as of September 28, 2026, including cardiac procedures and long-distance operations. The company's installed base reached 244 SSi Mantra systems, up 45% from the end of 2025, while cumulative procedures totaled 14,503. This growth underscores the increasing acceptance of remote surgical technologies, which could address surgeon shortages and improve access to specialized care in underserved regions.
Dr. Sudhir Srivastava, founder and CEO of SS Innovations and a cardiac surgeon, told MedTech Dive that robotic surgery is inherently a form of teleoperation, and the critical technical challenge is determining how much distance can be introduced without compromising responsiveness. The MedTech Dive report, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology's development and the regulatory and infrastructure questions surrounding remote surgery. It featured SS Innovations alongside larger medical-device companies and emerging robotics developers, signaling the company's growing relevance in a market that is attracting significant attention.
The implications of this trend are substantial for investors and the healthcare industry. As telerobotic surgery gains ground, companies that have accumulated real-world experience and robust data may have a competitive advantage. SS Innovations has expanded its SSi Mantra system into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka, and a new program established at HCG Hospital in Ahmedabad. These initiatives demonstrate the system's versatility and the company's ability to adapt to different healthcare environments. Moreover, SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking, which would open doors to two of the largest medical markets in the world. Successful clearance could significantly accelerate adoption and revenue growth.
The broader context is that telerobotic surgery could revolutionize surgical care by enabling expert surgeons to operate on patients thousands of miles away. This has profound implications for rural areas, disaster zones, and regions with limited access to specialized surgeons. However, regulatory hurdles and infrastructure requirements, such as reliable low-latency networks, remain challenges. The MedTech Dive article likely explored these issues, and SS Innovations' experience with 195 telesurgeries provides valuable insights for regulators and healthcare providers.
For SS Innovations, the recognition in a prominent industry publication like MedTech Dive is a validation of its technology and strategy. The company's newsroom at https://ibn.fm/SSII offers ongoing updates. As the demand for remote surgical solutions grows, SS Innovations is well-positioned to capitalize on this trend, provided it secures the necessary regulatory approvals and continues to demonstrate positive clinical outcomes. The company's progress will be closely watched by investors and industry stakeholders alike.
